STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval
Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
Stock Market Sleeps On Stereotaxis MAGiC CE Mark
Stereotaxis' MAGiC catheter received CE Mark approval in Europe, enabling the company to earn an additional $3k per procedure with +80% gross margins. FDA approval of MAGiC is expected by September. This will further drive recurring revenue and stock momentum. GenesisX's first order was announced. A successful practice will be pivotal for future orders which should begin after the commercial launch at the EHRA Congress in March/April.
STXS Stock Gains Following the First Order for its GenesisX
Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.
Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the manufacturing of its robotic mapping and guidecatheter for regulatory submissions in Q1 2025. STXS's holistic ecosystem approach, including interventional devices, GenesisX, and digital surgery advancements, aims to solve long-standing issues with robotic adoption in EP.
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Josh Jennings - TD Cowen Adam Maeder - Piper Sandler Operator Good afternoon. Thank you for joining us for Stereotaxis Third Quarter 2024 Earnings Conference Call.
Stereotaxis Inc. (STXS) Reports Q3 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval
GenesisX was approved in Europe and is set to be approved in the US late this year. The new robot is a giant leap forward in accessibility. Stereotaxis should get MAGiC approved in Europe in October. I expect a US approval no later than Q2 2025. The firm has enough cash to reach breakeven. It won't hire a lot of people right away to sell GenesisX.
Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX
Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.
Stereotaxis (STXS) Receives European Approval for GenesisX
Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.
